Ameriprise
EPRX

Ameriprise’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Ameriprise’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.7M Buy
711,024
+61,950
+10% +$427K ﹤0.01% 2591
2026
Q1 		$4.7M Buy
+649,074
New +$5.22M ﹤0.01% 2467

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Ameriprise's EPRX Position: Q2 2026 in Review

Ameriprise increased its Eupraxia Pharmaceuticals (EPRX) stake by 9.5% in Q2 2026, buying an estimated $427K and bringing the position to 711,024 shares worth $4.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2591.

Ameriprise first reported a position in EPRX in Q1 2026 and has held it in 2 quarters since. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Ameriprise held 711,024 shares of Eupraxia Pharmaceuticals worth $4.7M as of Q2 2026.
  • Ameriprise bought 61,950 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $427K.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2591 holding.
  • Ameriprise first reported a position in Eupraxia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.